comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 07:38:47 - browse：9924

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Home health providers sue Medicare over payment cuts

focus

WSS

Create a giant ice tray with this foil pan hack to keep food cold this summer

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Pandemic and All Hazards Preparedness Act needs lean update

A new drug could help frostbite victims avoid its ravages

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

entertainment

comprehensive

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Judge agrees to delay next hearing in Trump classified documents case

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Create a giant ice tray with this foil pan hack to keep food cold this summer

United colonoscopy coverage change 'may cost lives,' doctors say

ACA's risk program benefits Blue Cross Blue Shield insurers

What does generative AI mean for health care? We asked experts

Eisai exec who led development of Alzheimer’s drug to retire

entertainment

The U.S. needs a new definition of substance use “recovery”

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Eisai exec who led development of Alzheimer’s drug to retire

Ukraine seeks to reclaim its role as a hub for clinical trials

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Pandemic and All Hazards Preparedness Act needs lean update

Wikipedia

hotspot

focus

hotspot